Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1604-1608

  Allen, Ann ^a,b   Bygate, Elizabeth ^b   Oliver, Stuart ^d   Johnson, Martin ^d   Ward, Christopher ^d   Cheon, Ae Jin ^c   Choo, Youn Sung ^c   Kim, In Chull ^c  

^a Drug Metab and Pharmacokin Dept   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c LG Chemical Ltd   (South Korea)

^d The Frythe ^*

Author keywords

[No Author keywords available]

Indexed keywords

GEMIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; NAPHTHYRIDINES; PREGNANCY;

EID: 0034118232     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1604-1608.2000     Document Type: Article

References (6)

1. Cormican, M. G., and R. N. Jones. 1997. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:204-211.
2. Erwin, M. E., and R. N. Jones. 1999. Studies to establish quality control ranges for SB-265805 (LB20304) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. J. Clin. Microbiol. 37:279-280.
3. Gibaldi, M., and D. Perier. 1982. Pharmacokinetics, 2nd ed., p. 45-111. Marcel Dekker, Inc., New York, N.Y.
4. Hohl, A. F., R. Frei, V. Pünter, A. von Graevenitz, C. Knapp, J. Washington, D. Johnson, and R. N. Jones. 1998. International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin. Microbiol. Infect. 4:280-284.
5. Johnson, D. M., R. N. Jones, and M. E. Erwin. 1999. Anti-streptococcal activity of SB-265805 (LB20304) a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagn. Microbiol. Infect. Dis. 33:87-91.
6. Oh, J.-I., K.-S. Paek, M.-J. Ahn, M.-Y. Kim, C. Y. Hong, I.-C. Kim, and J.-H. Kwak. 1996. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimiciob. Agents Chemother. 40:1564-1568.